TRX 3Alternative Names: TolerMab Anti-CD2 monoclonal antibody; TRX3; TRX3 antibody - TolerRx
Latest Information Update: 01 Sep 2005
At a glance
- Originator TolerRx
- Class Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 01 Sep 2005 Discontinued - Preclinical for Psoriasis in USA (unspecified route)
- 05 Feb 2003 Preclinical trials in Psoriasis in USA (unspecified route)